Introduction {#sec1-1}
============

In this clinical science, all concepts are having its practical utility. One of the concepts is *Guna*, which has multifold meanings according to its use, in social, cultural, philosophical clinical, and literary fields.\[[@ref1]\]

In *Ayurveda*, *Gunas* have been classified under various categories like *Adhyatmika Guna, Gurvadi Guna, Paradi Guna, Visistha Guna*, etc.\[[@ref3]\] For the treatment purpose, *Gurvadi Gunas* are widely used. The *Guna* is related with *Dravya* in a *Samavaya* relationship. *Guna* exists till the *Dravya* keeps its existence. Similarly *Dravya* is also related to *Guna*. If the *Dravya* has no proper quality, it has no value.

The functional property of *Snigdha Guna* is *Sneha, Mrduta* (softness), and *Ardrata* (malleability).\[[@ref4][@ref5]\] It stimulates *Kapha* and normalizes *Vata* and also increases *Mala*. Similarly, the functional property of *Ruksa* is dryness. The property of *Ruksa Guna* is to increase the properties of *Vata* and normalizes the properties of *Kapha* and also decreases *Bala*, *Varna* (normal color). In the general treatment, two principles are adopted, i.e., *Santarpana* and *Apatarpana*. The increased elements are treated by opposite *Guna*. So if *Ruksa Guna* is increased then it is to be managed by *Snigdha Guna* and vice-versa.\[[@ref2]\] So diseases can be treated by applying the two *Gunas*, and drugs for the required patient can be selected by applying these *Gunas*.

In this study, the condition selected is *Rasa-raktagata Sneha* (hyperlipidemia) for the assessment of the selected two *Gunas*. Though the disease is not described in *Ayurveda*, but the *Laksanas* find a scattered description. Lipids or the fat molecules can be compared to *Sneha Ansa* of the body, which is essential for body existence. As *Susruta* says
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When the *Sneha* is in a normal condition, it gives unctuousness, invigoration, luster, strength, and corpulence to the body, but when it is in a disturbed state, disease occurs, which can be termed as *Rasa-raktagata Sneha* (hyperlipidemia). Cholesterol is a fatty substance (a lipid) that is an important part of the outer lining (membrane) of cells in the body of animals. Cholesterol is also found in the blood circulation of humans. It originates from two major sources: dietary intake and liver production. Dietary cholesterol comes mainly from meat, poultry, fish, and dairy products. Organ meats, such as liver, are especially high in the cholesterol content, while foods of plant origin contain no cholesterol. After a meal, cholesterol is absorbed by the intestines into the blood circulation and is then packaged inside a protein coat. This cholesterol--protein coat complex is called a chylomicron.\[[@ref7][@ref8]\]

The liver is capable of removing cholesterol from the blood circulation as well as manufacturing cholesterol and secreting cholesterol into the blood circulation. After a meal, the liver removes chylomicrons from the blood circulation. Between meals, the liver manufactures and secretes cholesterol back into the blood circulation.

Hence the assessment of *Snigdha Guna* can be possible in hyperlipidemia patients in objective and subjective criteria and *Ruksa Guna* drugs can be used for treatment. So this work was done to establish the two *Gunas*.

Materials and Methods {#sec1-2}
=====================

Conceptual study {#sec2-1}
----------------

For this study, the basic and conceptual materials were collected from the *Ayurvedic* classics, namely, *Brihatrayee* and *Laghutrayee*, other texts, literature in Modern science concerned with these principles, scientific journals, dissertations, research papers, etc.

Plant material {#sec2-2}
--------------

The plants selected had *Ruksa*, the dominant property in *Rasa Pancaka*. The test drug was prepared by selecting drugs, *Vaca, Kustha, Haridra, Daruharidra, Citraka*, and *Karanja*, in equal amounts. The raw drugs were made into a fine powder separately. The tablet was prepared of 500 mg each by giving *Bhavana* of *Karanja* bark decoction.

Study design {#sec2-3}
------------

The clinical study was conducted in two groups. The first, treatment group, was prescribed with prepared tablets (4 tabs bd 500 mg each) with diet control and the control group patients were treated with placebo (wheat powder in a tablet form) and diet control. The patients were randomly selected from the OPD and IPD of the Basic Principles Department of the hospital of the Institute of Post graduate Teaching and Research in Ayurveda, Jamnagar, Gujarat.

Ethical clearance {#sec2-4}
-----------------

The institutional ethics committee approved the study. The oral consent was taken from each patient who willingly participated in the study. Patients were free to withdraw from the study at any point of time for any reason and they were not forced to continue the treatment. All the benefits and possible hazards were narrated to the patients without any discrimination.

Selection of patients {#sec2-5}
---------------------

The inclusion criteria were as follows:

patients between 20 and 60 years of ageHyperlipidemic patientsPatients having *Snigdha Guna* increased in their body elements like *Dosa*, *Dhatu*, and *Mala*.The exclusion criteria were as follows:

Patients below 20 years and above 60 years of agePatients having weight more than 100 kg (overweight)Obesity associated with any other complicated conditions like cardiac problems, endocrinal disorders, etc.

Assessment criteria {#sec2-6}
-------------------

The overall effect was decided on the basis of improvement in *Snigdha Ansa* in the body and biochemical parameters (lipid profile):

Improvement in *Snigdha Guna*.Improvement in the lipid profile, i.e., serum cholesterol and serum triglyceride.

In this part, percentage improvement in serum cholesterol and serum triglycerides was assessed and then the average of both the percentage improvements was taken to assess the overall effect of therapy. Thus, the total effect of the therapies was marked as following:
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The special scoring pattern for *Sarvangavayava Snigdhata*\[[@ref9]--[@ref13]\] was as follows:
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Drug delivery and duration {#sec2-7}
--------------------------

The treatment group was prescribed with prepared tablets (4 tabs 500 mg each, bd) with diet control and the control group patients were treated with placebo in a tablet form (4 tabs, 500 mg each, bd, with lukewarm water in *Apana Kala*) and diet control for 45 days.

Follow-up of treatment {#sec2-8}
----------------------

Each patient was assessed on the basis of a special scoring pattern to provide objectivity to the subjective parameters. The clinical improvement/aggravation of the symptoms was regularly recorded.

The following were the criteria of withdrawal of the patients:

Irregular patients.Those failing to follow the prescribed dietary regimen.Patients who abstained from the follow-up.Any adverse/emergency condition needing immediate attention.

Statistical tests {#sec2-9}
-----------------

All the observations made for various parameters were subjected to statistical analysis in terms of mean (*X*), standard deviation (SD), and standard error (SE). A paired *t*-test was carried out at *P*\<0.05, *P*\<0.01, and *P*\<0.001. The obtained results were interpreted as follows: insignificant *P*\>0.05; significant *P*\<0.05; highly significant *P*\<0.01, *P*\<0.001.

Results {#sec1-3}
=======

A total of 150 persons with *Rasa-raktagata Sneha* were registered and randomly divided into two groups: 74 subjects in Group A and 76 in Group B. A total of 110 patients, 56 patients in Group A and 54 patients in Group B, completed the course of therapy; 40 patients discontinued it.

The maximum number of patients, i.e., 40.67% patients, belonged to the age group of 41--50 years; 54.67% patients were males, 82.00% patients were from the Hindu community, 49.34% patients were educated, i.e., educated till Higher Secondary. Socioeconomically, 56.66% subjects were from middle class, and 41.33% patients were doing business. In terms of *Prakrti*, 53.34% subjects of the study population belonged to *Kapha-Vata Prakrti*, 56.66% patients were having *Rajasika Prakrti*, 50.00% of patients were having *Avara Vyayama Sakti*, and 52.00% subjects were possessing *Visamagni*. A total of 48.66% patients were having a dietetic habit of *Adhyasana* (25.34% patients were having a habit of *Atyasana*). In terms of *Ahara*, 58.00% patients were taking a *Niramisa* diet; among the nonvegetarian patients, 20.67% patients were having egg-dominant nonvegetarian food. A total of 56.00% patients were using groundnut oil in their diet; 53.33% patients were taking tea and 68.00% were taking *Madhura Rasa*-dominant food.

Regarding the onset of the disease, 96.66% persons were having a negative family history of hyperlipidemia, and 38.00% patients were having a positive family history of obesity. *Aharatamaka Nidana* was reported as *Snigdh Ahara* in 87.24% patients, *Atibhojana Matra* in 61.08% patients, *Guruahara* in 73.16%, *Atimadhura Ahara* in 57.04%, *Dadhi sevana* in 53.69% patients, and in 39.59% patients, *Atisita Ahara sevana* was observed.

*Viharatmaka Nidana* recorded in present series was *Diwaswapana* in 84.56% persons, *Sukhasayan* and *Bhojonottara Nidra* each in 69.79% persons, *Avyayama* in 39.59%, and *Avyavaya* in 29.53%.

*Manasa Nidana* reported that in the present series 45.63% persons were having *Achinta*, and *Manasanivriti* and *Priya Darsana* each was found in 40.93% persons. *Harsanityatvat* was present in 35.57% cases.

Maximum patients, i.e., 40.00% cases, were having BMI in the range of 26--30 kg/m^2^; 51.33% cases were having serum cholesterol in the range of 201--250 mg/dl, 44.66% were having serum triglyceride in the range of 151--250 mg/dl, 53.33% cases were having serum HDL up to 40 mg/dl, 64.00% persons were having serum LDL up to 130 mg/dl, and 50.00% cases were having serum VLDL up to 40 mg/dl.

Effect of therapy {#sec2-10}
-----------------

The following observations were made:

It was observed that in *Sarvangavayava Snigdhata* in Group A, better results were seen at *Sarvanga Tvak, Lalata, Karna Pradesa*, etc. Reduction in *Snigdha Guna* was observed which was statistically highly significant. In Group B, no significant result was observed \[Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}\].The result of serum LDL is very mild, but increasing result of serum HDL was not observed as it should be increased after treatment. According to aim of the study on the treatment of hyperlipidemia condition, serum HDL should be increased and decreasing result of LDL. The control group had no change except for the minor change in the serum cholesterol level. It can be said the hypothesis is fulfilled by the lipid profile test results. In Group A, better results could have been achieved if the duration was long, up to 3 months, as the 45-day treatment duration may be not sufficient for getting the desired results in the case of serum LDL \[Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}\].On comparison of effects of therapy on Groups A and B in terms of *Sarvangavayava Snigdhata*, Group A showed significant results in all the *Laksanas* compared to Group B. So the therapy was more effective in Group A.On comparison of the effects of therapy on Groups A and B in terms of the improvement in serum cholesterol, serum triglyceride, serum HDL, serum LDL, and serum VLDL, serum triglyceride and serum VLDL had statistically significant results in Group A compared to Group B.In terms of *Sarvangavayava Snigdhata* in Group A, 23.21% patients markedly improved, 69.64% cases moderately improved, while 1.78% persons showed minor improvements, and rest 5.36% persons remained unchanged.

###### 

Effect of the *Ruksa Guna* drugs on *Sarvangavayava Snigdhata Laksanas* found in 56 persons of *Rasa-raktagata Sneha* of Group 'A'
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###### 

Effect of the control on *Sarvangavayava Snigdhata Laksanas* found in 54 persons of *Rasa-raktagata Sneha* of Group 'B'
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###### 

Effect of the *Ruksa Guna* drugs on the lipid profile found in 56 persons of *Rasa-raktagata Sneha* of Group 'A'
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###### 

Effect of the control on the lipid profile found in 54 persons of *Rasa-raktagata Sneha* of Group 'B'
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In the case of *Sarvangavayava Snigdhata* in Group B, 61.12% persons remained unchanged, 25.92% persons showed minor improvement, 12.96% persons moderately improved \[[Figure 1](#F1){ref-type="fig"}\].

![Effect of therapy in Groups A and B on *Sarvangavayava Snigdhata*](Ayu-32-200-g008){#F1}

The serum cholesterol level in Group A showed that 57.14% persons remain unchanged, 37.5% persons showed minor improvement, and 7.14% persons showed a moderate improvement.

The serum cholesterol level in the control group revealed that 70.37% persons remain unchanged, 14.81% persons showed minor improvement, 12.96% persons showed a moderate improvement \[[Figure 2](#F2){ref-type="fig"}\].
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Data for serum triglycerides in Group A showed that 25.00% persons remained unchanged, 23.22% persons showed a minor improvement, 30.36% patients showed a moderate improvement, and 19.64% persons showed a marked improvement.

Data for serum triglycerides in Group B showed that 55.55% persons remained unchanged, 14.82% persons showed minor improvements, 24.07% persons showed moderate improvements, and 3.71% persons showed marked improvements \[[Figure 3](#F3){ref-type="fig"}\].

![Effect of therapy in Groups A and B on serum triglycerides](Ayu-32-200-g010){#F3}

Discussion {#sec1-4}
==========

In *Ayurveda*, *Gunas* are described as the way of presentation or action without which no *Karma* can be performed. The *Karanasatak* and *Hetu, Linga*, and *Ausadha Skandha* have also been described in terms of *Gunas*. Though the very science keeps a similarity view on *Samkhya* and *Vaisesikas Darsanas*, the description of the concept of *Guna* differs. *Ayurveda* has provided new connotations to every *Guna* so that they become useful in clinical practice. Coming to the *Ayurvedic* concept of *Guna*, *Caraka*\'*s* view seems closer to *Darsana Sastras*.

In this clinical study, an attempt was made to evaluate the effect of *Ruksa Guna* drugs on *Snigdha Guna* of the body under the conditions like *Rasa-raktagata Sneha* (hyperlipidemia), assuming that this is the case of increased *Snigdha Guna*.

After observing the *Snigdha Guna* of *Dosa Dhatu* and *Mala*, externally *Snigdhata* was assessed in each part of the body. For this, one specific scoring pattern was prepared for 15 criteria for 15 areas of the body and implemented on the persons to observe the role of *Ruksa Guna* in the body. After the proper administration of test drugs (*Ruksa Guna*) and control, the results were as follows. In the the treated group, better results were seen for *Snigdhata* on *Sarvanga Tvak*, *Lalata*, *Karna Pradesa*, etc.; up to 52.13% reduction in *Snigdha Guna* was observed which is statistically highly significant (*P*\<0.001). In the control group, no *Snigdhata* result was observed and all the results were statistically insignificant (*P*\>0.05).

In the treated group, better results were observed, because *Ruksa Guna* had a good action on *Snigdha Guna* of body. The principle adopted by *Caraka* is
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Again *Arunadutta* advocates that
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*Tvaca* has covered all over the body. *Rasa* *Dhatu* flows interruptedly on the, *Tvaca* as well as whole body with the help of *Srotas*. If *Snigdha Guna* increases in *Rasa Dhatu*, then the *Snigdhata* of the skin increases too. So the *Snigdhata* will be seen in the body. In this study, maximum *Snigdhata* was seen at *Lalata* and *Karna Pradesa*.

According to the aim of the treatment of hyperlipidemia, serum HDL should be increased. The change in serum LDL was very mild, but an increase in serum HDL was not observed. In the control group, there was no change except for a minor change in serum cholesterol. It can be said the hypothesis is positively supported by the result of lipid profile test. In the treated group, better results could have been found if the duration was increased, up to 3 months, as the 45-day treatment duration may be not sufficient for getting the desired result in the case of serum LDL.

As weight and BMI both are interrelated, as weight reduced, BMI also reduced. In the medicinal Group A, results were seen due to the exercise, diet control, and the *Ruksa* drugs.

The prepared drug was not toxic to the body as after the administration of Group A, there was a decrease in serum uric acid with the decrease in weight. So it is a safe drug and is helpful in peripheral arterial diseases.

The *Ruksa Guna* prepared drug in Group A was able to decrease the *Snigdha Guna* of the body as well as helpful in increasing the *Dipana Pacana* activity of liver. As the serum alkaline phosphatase level reduced by 14.94%, it seems the liver function was increased during the period of medication.

Conclusion {#sec1-5}
==========

In the end, it can be concluded that hyperlipidemia can be treated by *Ruksa Guna* property drugs assuming the condition to be an increase in *Snigdha Guna*. On the basis of the Guna concept, the applied medicine of *Ayurveda* could be developed.
